ESC 365 - Clinical scenario 3: Interpreting the evidence base for rivaroxaban in the treatment of cancer-associated thrombosis: What does it mean for your patient?

Open Access

Clinical scenario 3: Interpreting the evidence base for rivaroxaban in the treatment of cancer-associated thrombosis: What does it mean for your patient?

Session: Treatment challenges in VTE: Exploring solutions with rivaroxaban across three clinical scenarios

Topic: Venous Thromboembolism

Speaker: Doctor A. Khorana

Sponsored by Bayer AG

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Alok Khorana

1 presentation

0 follower

6 more presentations in this session

Welcome and introduction.

Speaker: Professor S. Konstantinides (Mainz, DE)

Clinical scenario 1: Anticoagulation for patients with pulmonary embolism from hospital to home: Insights from the 2019 ESC PE guideline updates and HOT-PE trial.

Speaker: Professor S. Konstantinides (Mainz, DE)

Q&A.

Clinical scenario 2: Identifying patients eligible for extended VTE treatment: Insights from EINSTEIN CHOICE and EINSTEIN EXT.

Speaker: Professor J. Weitz (Hamilton, CA)

Q&A.

Access the full session

Treatment challenges in VTE: Exploring solutions with rivaroxaban across three clinical scenarios

Speakers: Doctor A. Khorana, Professor S. Konstantinides, Professor S. Konstantinides, Professor J. Weitz

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources